Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept

Background Atherosclerotic plaque phenotypes are classified based on the extent of macrophage infiltration into the lesions, and the presence of certain macrophage subsets might be a sign for plaque vulnerability. The mannose receptor (MR) is over-expressed in activated macrophages. Tilmanocept is a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EJNMMI research 2017-05, Vol.7 (1), p.40-40, Article 40
Hauptverfasser: Varasteh, Zohreh, Hyafil, Fabien, Anizan, Nadège, Diallo, Devy, Aid-Launais, Rachida, Mohanta, Sarajo, Li, Yuanfang, Braeuer, Miriam, Steiger, Katja, Vigne, Jonathan, Qin, Zhengtao, Nekolla, Stephan G., Fabre, Jean-Etienne, Döring, Yvonne, Le Guludec, Dominique, Habenicht, Andreas, Vera, David R., Schwaiger, Markus
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Atherosclerotic plaque phenotypes are classified based on the extent of macrophage infiltration into the lesions, and the presence of certain macrophage subsets might be a sign for plaque vulnerability. The mannose receptor (MR) is over-expressed in activated macrophages. Tilmanocept is a tracer that targets MR and is approved in Europe and the USA for the detection of sentinel lymph nodes. In this study, our aim was to evaluate the potential of 111 In-labelled tilmanocept for the detection of MR-positive macrophages in atherosclerotic plaques of apolipoprotein E-knockout (ApoE-KO) mouse model. Methods Tilmanocept was labelled with 111 In. The labelling stability and biodistribution of the tracer was first evaluated in control mice ( n  = 10) 1 h post injection (p.i.). For in vivo imaging studies, 111 In-tilmanocept was injected into ApoE-KO ( n  = 8) and control ( n  = 8) mice intravenously (i.v.). The mice were scanned 90 min p.i. using a dedicated animal SPECT/CT. For testing the specificity of 111 In-tilmanocept uptake in plaques, a group of ApoE-KO mice was co-injected with excess amount of non-labelled tilmanocept. For ex vivo imaging studies, the whole aortas ( n  = 9 from ApoE-KO and n  = 4 from control mice) were harvested free from adventitial tissue for Sudan IV staining and autoradiography. Cryosections were prepared for immunohistochemistry (IHC). Results 111 In radiolabelling of tilmanocept provided a yield of greater than 99%. After i.v. injection, 111 In-tilmanocept accumulated in vivo in MR-expressing organs (i.e. liver and spleen) and showed only low residual blood signal 1 h p.i. MR-binding specificity in receptor-positive organs was demonstrated by a 1.5- to 3-fold reduced uptake of 111 In-tilmanocept after co-injection of a blocking dose of non-labelled tilmanocept. Focal signal was detected in atherosclerotic plaques of ApoE-KO mice, whereas no signal was detected in the aortas of control mice. 111 In-tilmanocept uptake was detected in atherosclerotic plaques on autoradiography correlating well with Sudan IV-positive areas and associating with subendothelial accumulations of MR-positive macrophages as demonstrated by IHC. Conclusions After i.v. injection, 111 In-tilmanocept accumulated in MR-expressing organs and was associated with only low residual blood signal. In addition, 111 In-tilmanocept uptake was detected in atherosclerotic plaques of mice containing MR-expressing macrophages suggesting that tilmanocept represents
ISSN:2191-219X
2191-219X
DOI:10.1186/s13550-017-0287-y